AMPH NASDAQ
Amphastar Pharmaceuticals, Inc.
1W: -2.6%
1M: -2.5%
3M: +26.4%
YTD: -3.7%
1Y: +3.0%
3Y: -43.2%
5Y: +33.8%
$25.57
+0.10 (+0.39%)
After Hours: $24.50 (-1.07, -4.18%)
Weekly Expected Move ±4.8%
$23
$24
$25
$26
$28
Credit Risk of going bust: higher than 70% of companies Debt: 38.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.35 (down 95%), Amphastar Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $688.3M against a stock market value of $1.08B.
Distance to default 3.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.3M (short-term plus half of long-term), stock volatility 53.9%; Altman Z 2.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $1.35 (down 95%), Amphastar Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $688.3M against a stock market value of $1.08B.
Distance to default 3.43 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $307.3M (short-term plus half of long-term), stock volatility 53.9%; Altman Z 2.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships12
As Filer
counterparties named
2
As Counterparty
mentioned by others
2
Rel. Types
2021-05-25
Earliest Filing
2026-03-06
Latest Filing
partner: 10
supplier: 2
Counterparties (Filed by AMPH)
12 relationshipsCompanies named in AMPH's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Nanjing Letop Biotechnology Co., Ltd. | — | supplier | Supplier of chemical intermediates to Amphastar Nanjing Pharmaceuticals, Inc. | 2026-03-06 | View |
| Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | — | partner | Partner providing Research Cell Banks for Master Cell Bank development. | 2026-03-06 | View |
| Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | — | partner | Entered into a License Agreement granting exclusive rights to develop and commercialize corticotropin products in the US | 2026-01-12 | View |
| Armstrong Pharmaceuticals, Inc. | — | partner | Wholly-owned subsidiary of Amphastar that entered into an amendment to the Distribution Agreement. | 2026-01-12 | View |
| Hong Kong Genreach Limited | — | partner | Wholly-owned subsidiary of Hanxin that entered into an amendment to the Distribution Agreement. | 2026-01-12 | View |
| Amphastar Nanjing Pharmaceuticals, Inc. | — | partner | Chinese subsidiary of Amphastar that entered into an amendment to the Manufacturing Agreement. | 2026-01-12 | View |
| Nanjing Chengong Pharmaceutical Co., Limited | — | partner | Exclusive distributor for BAQSIMI in Greater China | 2025-10-24 | View |
| Nanjing Hanxin Pharmaceutical Technology Co., Ltd | — | partner | Parent company of Nanjing Chengong Pharmaceutical Co., Limited | 2025-10-24 | View |
| Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | — | partner | Contract research agreement for development and licensing of Recombinant Peptide Research Cell Banks (RCBs) for AMP-107. | 2025-09-18 | View |
| Nanjing Anji Biotechnology Co., Ltd. | — | partner | Entered into a License Agreement granting Amphastar an exclusive license to certain intellectual property for developing | 2025-08-12 | View |
| Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | — | partner | Contract research agreement for development and licensing of Recombinant Human Insulin Research Cell Banks | 2022-07-08 | View |
| Nanjing Hanxin Pharmaceutical Technology Co., Ltd. | — | supplier | Contract manufacturing agreement to develop active pharmaceutical ingredients and finished products for the Chinese mark | 2022-04-22 | View |
Mentioned As Counterparty
2 mentionsOther companies that named AMPH in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| MNKD MANNKIND CORP | customer | Amphastar Pharmaceuticals, Inc. is a supplier to MannKind Corporation under a Supply Agreement amended on December 22, 2 | 2023-12-27 | View |
| MNKD MANNKIND CORP | customer | Sixth Amendment to Supply Agreement extending term to 2027 and restructuring purchase commitments. | 2021-05-25 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-13 | Officer/Director Change | View | |
| 2026-07-08 | Other Events | View | |
| 2026-06-03 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-16 | Other Events | View | |
| 2026-03-06 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-03-06 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-09-18 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-08-12 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-21 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-04 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR